PYR 41Cat. No. 2978 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 4-[4-[(5-Nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]benzoic acid ethyl ester |
Biological Activity
Cell-permeable, irreversible ubiquitin-activating enzyme (E1) inhibitor (IC50 < 10 μM). Blocks ubiquitylation and prevents ubiquitin-mediated proteasomal degradation. Inhibits NF-κB activation, blocks degradation of p53, increases p21 levels and induces apoptosis in vitro. Also causes an increase in sumoylation of proteins.Certificate of Analysis / Safety Data Sheet
References
Yang et al (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67 9472. PMID: 17909057.
Mi et al (2009) Cancer preventative isothiocyanates induce selective degradation of cellular α- and β-tubulins by proteasomes. J.Biol.Chem. 284 17039. PMID: 19339240.
Brahemi et al (2010) Homology modelling of human E1 ubiquitin activating enzyme. Lett.Drug Des.Discov. 7 57. PMID: 20396627.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: PYR 41, supplier, PYR41, ubiquitin-activating, enzyme, E1, inhibitors, ubiquitylation, post-translational, modifications, proteasomal, proteasome, sumoylation, sumo, ubiquitin
Quick Order
Find multiple products by catalog number
New Products in this Area
Irreversible mitochondrial respiratory complex II inhibitor
CapecitabineProdrug of 5-Fluorouracil (Cat. No. 3257). Inhibits DNA synthesis
8-ChloroadenosineCytotoxic nucleoside analog; inhibits RNA synthesis
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

